This could be good news for the companies, because up until now Onglyza has done poorly in the market.

FORBES: Good News For Bristol and Astra -- Maybe

Bristol-Myers Squibb and AstraZeneca announced today that the Food and Drug Administration has approved their diabetes pill Kombiglyze, which combines the diabetes drug Onglyza with metformin, a generic drug.

FORBES: Good News For Bristol and Astra -- Maybe

Bristol-Myers Squibb ( BMY - news - people ) learned that the Food and Drug Administration is extending until July 30 (from April 30) the time it is taking to review their application for the Type 2 diabetes treatment, saxagliptin, also known by its commercial name, Onglyza.

FORBES: Stock Of The Week